n ambitious UK government effort to help underwrite the cost of cancer treatments may have been a worthless bust, according to a new analysis.

Known as the Cancer Drugs Fund, the program was established in 2010 to provide patients with access to cancer drugs not available through the National Health Service because the treatments were not viewed as cost effective by a separate UK government agency. Since then, the fund has spent about $1.5 billion to treat some 100,000 people, although more recently, its finances have been strained.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.